Jeffrey Burns, MD
Neurology · Kansas City, KSNPI 1780781377
Payments from drug & device makers
Across 249 payments — averaging $25,053 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2.2M
- Biogen$1.4M
- AstraZeneca$946K
- AbbVie$795K
- Novartis$644K
- Eisai Inc.$78K
- plus $220K from 10 others
Across 9 payments — averaging $1319.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9K
- Sage Therapeutics, LLC$3K
What the payments were for
- Consulting fees$103,25689%
- Travel & lodging$9,9689%
- Food & beverage$2,2432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 61 | $2,198,997 |
| Biogen | 16 | $1,355,731 |
| AstraZeneca | 6 | $946,053 |
| AbbVie | 75 | $794,801 |
| Novartis | 5 | $643,945 |
| Eisai Inc. | 24 | $78,391 |
| Janssen Research & Development, LLC | 2 | $55,758 |
| Hyperfine Operations, Inc. | 2 | $54,892 |
| Lilly USA, LLC | 37 | $52,577 |
| Genentech, Inc. | 4 | $30,272 |
| Novo Nordisk | 8 | $10,373 |
| Ionis Pharmaceuticals, Inc. | 5 | $7,783 |
| Roche Diagnostics Corporation | 1 | $3,348 |
| Avanir Pharmaceuticals, Inc. | 1 | $2,616 |
| Sage Therapeutics, LLC | 1 | $2,500 |
| Merck | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,238,099 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 46 | $7,178 |
| Donepezil Hcl | 516 | $5,542 |
| Galantamine ErGalantamine Hbr | 50 | $4,163 |
| Memantine Hcl | 137 | $3,207 |
| Escitalopram Oxalate | 124 | $1,369 |
| Quetiapine Fumarate | 43 | $688 |
| Sertraline Hcl | 47 | $277 |
| Trazodone Hcl | 26 | $150 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Sharon LynchKansas City$9.3M
- Rajesh PahwaKansas City$5M
- Mamatha PasnoorKansas City$3.9M
- Constantine FarmakidisKansas City$649K
- Richard DubinskyKansas City$261K
- Patrick LandazuriKansas City$256K
- Michael AbrahamKansas City$203K
- Omar JawdatKansas City$111K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.